When experimental brain metastasis were established from intra-carotid injected human NSCLC cells harboring a EGFR exon 19 deletion, the third-generation EGFR inhibitor Osimertinib achieved sustained tumor regression and extended mice survival.67 This benefit of Osimertinib was later recapitulated in a randomized phase III trial, in which the compound showed good intracranial activity and was able to prolong disease-free survival in patients with CNS disease.68 The gene discussed is EGFR; the disease is neoplasm.